Skip to main content

General Principles of Treatment

  • Chapter
Vasculitis in Clinical Practice

Abstract

The type of vasculitis and the extent of organ involvement guide treatment. The intensity of initial immunosuppression depends on the severity of organ involvement and the size of the vessels involved (Table 4.1). Therefore, an important part of treatment planning involves the assessment of organ involvement and its severity. Treatment may be divided into remission induction, maintenance, and long-term follow-up. Guidelines on the management of the vasculitides have been recently published [1–3]. In this chapter, we will cover the general principles of treatment and the agents used.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR/BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology. 2014;53(12):2306–9.

    Article  PubMed  Google Scholar 

  2. Mukhtyar C, Guillevin L, Cid M, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68:318–23.

    Article  CAS  PubMed  Google Scholar 

  3. Mukhtyar C, Guillevin L, Cid M, et al. EULAR recommendations for the management of primary small and medium vasculitis. Ann Rheum Dis. 2009;68:310–7.

    Article  CAS  PubMed  Google Scholar 

  4. Jayne D, Rasmussen N, Andrassy K, et al. A randomised trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic auto antibodies. N Engl J Med. 2003;349:36–44.

    Article  CAS  PubMed  Google Scholar 

  5. Pagnoux C, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790–803.

    Article  CAS  PubMed  Google Scholar 

  6. de Groot K, Harper L, Jayne DR, et al. Pulse versus oral cyclophosphamide for induction of remission in anti-neutrophil cytoplasmic antibody associated vasculitis: a randomised trial. Ann Intern Med. 2009;150:670–80.

    Article  PubMed  Google Scholar 

  7. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–20.

    Article  CAS  PubMed  Google Scholar 

  8. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. de Groot K, Rasmussen N, Bacon P, et al. Randomised trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody associated vasculitis. Arthritis Rheum. 2005;52:2462–8.

    Article  Google Scholar 

  10. Jayne DR, Gaskin G, Rasmussen N, et al. Randomised trial of plasma exchange and high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing AG, Cham

About this chapter

Cite this chapter

Watts, R.A., Scott, D.G.I., Mukhtyar, C. (2015). General Principles of Treatment. In: Vasculitis in Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-14871-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-14871-7_4

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-14870-0

  • Online ISBN: 978-3-319-14871-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics